17.04.2023 05:30:19
|
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
(RTTNews) - Satsuma Pharmaceuticals Inc. (STSA) agreed to be acquired by Shin Nippon Biomedical Laboratories Ltd. for $0.91 in cash per share at the closing of the transaction plus one non-tradeable contingent value right of up to $5.77 per share.
The contingent value right is payable pursuant to the future sale, license, or any other monetization events related to STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine.
Satsuma submitted a New Drug Application to the U.S. Food and Drug Administration in March 2023 for STS101, which incorporates nasal powder formulation and delivery device technologies developed by SNBL and exclusively licensed by Satsuma.
Satsuma Board of Directors recommends that Satsuma stockholders tender their shares in the Tender Offer.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Satsuma Pharmaceuticals Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Satsuma Pharmaceuticals Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Satsuma Pharmaceuticals Inc Registered Shs | 0,98 | 4,84% |